PDCD1LG2 and Hodgkins lymphoma: Sintilimab, a fully human IgG4 monoclonal antibody which can bind to PD‐1 to block the interaction of PD‐1 with PD‐L1 and PD‐L2, has demonstrated its antitumor activity and safety in classical Hodgkin's lymphoma.